When the U.S. Food and Drug Administration first approved Invokana in 2013, it was hailed as a breakthrough drug to treat adults with type 2 diabetes. The medication ushered in a new class of drugs called SGLT2 inhibitors that were meant to be a safe and effective treatment option.
Within months of approval, users started reporting serious and unexpected side effects that resulted in hospitalization, amputations of the limbs, and even death. This prompted the FDA to take action by issuing several warnings about side effects.
But to those affected by Invokana, it was not enough.
Hundreds of people have filed lawsuits against Johnson & Johnson and its subsidiary Janssen Pharmaceuticals. Plaintiffs are making several allegations against the companies, including a failure to warn of dangers, negligence, creating a defective drug, and more. The first trials are set to take place in September 2018.